An option for oncological patients with limited therapeutic paths
“Approximately 20% of breast cancer patients and between 40 and 50% of lung cancer patients develop brain metastases»Sources of Medsir. The treatment options in these cases are limited. But a new study presented yesterday by this International Medical Research Company during the Annual Meeting of the American Society of Clinical Oncology (Asco) could bring Esperanza.
Financed by Daiichi Sankyo Company and MSD, the essay «Tuxedo-3 »in phase II evaluates the effectiveness and safety of a new drug, Patritumab deruxtecán (her3-dxd), For patients with breast or lung cancer with active brain metastases, as well as for patients with leptomeníníngea derived from solid tumors, a serious condition by which tumor cells spread from primary cancer to meninges.
Her3-DXD is a conjugate antibody-symptoms that combines Patritumab, an anti-Her3 IgG1 human monoclonal antibody that binds to topoisomerase I (Deruxtecan, a derivative of ex-order). Deruxtecan technology, which is part of the antibody-drugged conjugate, is an agent that causes damage to tumor DNA, which destroys cancer cells.
The results published in “Nature Medicine” speak for themselves. Those patients who had already received antibody-drug conjugate responded positively to the new treatment. Thus, patients with breast cancer and active brain metastasis had intracranial responses in all breast cancer subtypes, including the luminal, her2+ and triple negative.
In patients with advanced non -microcytic lung cancer with active brain metastasis, researchers observed intracranial responses both in those with mutations in the epidermal growth factor receptor and those that not.
These data suggest that Her3-DXD could offer a new treatment option in patients with secondary affectation of the central nervous system. That is to say, that this drug in research that today continues to receive patients in some Spanish hospitals can suppose an option for these patients who have few therapeutic alternatives.
The study fulfilled its objectives by achieving that 23.8 and 30% of patients had intracranial responses in active brain metastasis with the type lung cancer cited with active cerebral metastasis and active brain metastasis, respectively.
In addition, a 65% of patients with leptomenínngea were still alive three months later.
As for side effects, these were serious on rare occasions, in about 5% of patients. Specifically, according to the data provided, “the adverse effect of grade 3 to 5 (range from 1 to 5) more common in the three groups of patients was neutropenia,” a low number of a type of white blood cells in the blood.
Regarding the quality of life and neurocognitive functions, the tests showed that the participants remained stable or improved over time.
“This study represents a significant advance in our understanding on how «Tuxedo-3».
“Cerebral metastasis and leptomenínngea represent serious complications in cancer, which lead to an increase in morbidity and mortality, and her3-DXD could be a promising therapeutic alternative,” adds Rupert Bartsch, main co-investigator.
Other studies
Medsir also presented the results of “Adela” and “Win-B”. The first is a current phase III study focused on developing transforming treatments for cancer patients in order to delay disease progression. Regarding the second, it is an IB/II phase trial that evaluates the preliminary safety and efficacy of the combination of an inhibitor and a conjugate antibody-symptoms in advanced breast cancers HR+/her2- and triple negative.